Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE)

Focal and Segmental Glomerulosclerosis, Minimal Change Disease and Membranous Nephropathy, presenting as Nephrotic Syndrome (NS), are a group of rare renal diseases that may cause serious complications and end-stage kidney disease, generating significant individual, societal and economic burdens. The Nephrotic Syndrome Study Network (NEPTUNE) brings together physician scientists at 26 sites in the United States and Canada, along with patient advocacy groups to advance research on these diseases. Already, NEPTUNE has established a rich translational and clinical research infrastructure for more than 750 rigorously phenotyped study participants with detailed clinical, histological, genetic, transcriptomic and proteomic data sets. Using a systems biology, NEPTUNE applies a precision medicine approach to define NS in molecular terms, identifies novel therapeutic targets and is testing strategies to match patients to their right treatments tested in ongoing clinical trials.

The Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Office of Rare Diseases Research (ORDR). NEPTUNE is funded under grant number U54DK083912 as a collaboration between NCATS and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).